CLCD CoLucid Pharmaceuticals, Inc.

46.53
+0  (0%)
Previous Close 46.53
Open 0.00
Price To book 0.00
Market Cap N/A
Shares 0
Volume 0
Short Ratio 0.00
Av. Daily Volume 543,728

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2H 2017. To be acquired by LLY.
Lasmiditan - SPARTAN
Migraine
Phase 3 top-line data met endpoints - September 6, 2016. To be acquired by LLY 1Q 2017.
Lasmiditan - SAMURAI
Migraine

Latest News

  1. Lilly Completes Acquisition of CoLucid Pharmaceuticals
  2. INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders
  3. Bragar Eagel & Squire, P.C. Is Investigating the Board of Directors of CoLucid Pharmaceuticals, Inc. (CLCD) on Behalf of Stockholders and Encourages Investors to Contact the Firm
  4. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders -- CLCD
  5. INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information
  6. INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders -- CLCD
  7. Acorda Could Rival Lilly's 'Novel' Migraine Drug With Faster Onset
  8. SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
  9. SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of CoLucid Pharmaceuticals, Inc. -CLCD
  10. COLUCID SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of CoLucid Pharmaceuticals, Inc. (CLCD) Over the Proposed Sale of the Company to Eli Lilly and Company
  11. Robbins Arroyo LLP: Acquisition of CoLucid Pharmaceuticals, Inc. (CLCD) by Eli Lilly and Company (LLY) May Not Be in Shareholders' Best Interests
  12. Here's Why CoLucid Pharmaceuticals Inc Popped Yesterday
  13. Here’s What You Need To Know About The Eli Lilly And Co (LLY) And CoLucid Pharmaceuticals Inc (CLCD) Deal
  14. Eli Lilly and Company -- Moody's: Eli Lilly and Company's acquisition of pipeline-stage asset is credit negative
  15. Lilly to Boost Migraine Pipeline with $960M CoLucid Buyout
  16. Blog Coverage Eli Lilly Announced Acquisition of CoLucid; Adds Lasmiditan to the Pain Management Portfolio
  17. Why Fastenal, Mead Johnson Nutrition, and CoLucid Pharmaceuticals Jumped Today